|
|
Volumn 173, Issue 4, 2005, Pages 347-348
|
|
Patient demand and politics push Herceptin forward.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
ARTICLE;
BREAST TUMOR;
CANADA;
CLINICAL PRACTICE;
ECONOMICS;
FEMALE;
HUMAN;
METASTASIS;
ORGANIZATION AND MANAGEMENT;
PATHOLOGY;
PATIENT PARTICIPATION;
PUBLIC HEALTH;
STATISTICS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CANADA;
ELIGIBILITY DETERMINATION;
FEMALE;
HUMANS;
NATIONAL HEALTH PROGRAMS;
NEOPLASM METASTASIS;
PATIENT PARTICIPATION;
PHYSICIAN'S PRACTICE PATTERNS;
RECEPTOR, ERBB-2;
|
|
EID: 26944498696
PISSN: None
EISSN: 14882329
Source Type: Journal
DOI: 10.1503/cmaj.050883 Document Type: Article |
|
Times cited : (12)
|
|
References (0)
|
